Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
J Healthc Eng. 2021 Dec 23;2021:9543912. doi: 10.1155/2021/9543912. eCollection 2021.
Secondary prevention therapy reduces death and reinfarction after acute myocardial infarction (AMI), but it is underutilized in clinical practice. Mechanisms for this therapeutic gap are not well established. In this study, we have explored and evaluated the impact of passive continuation compared to active initiation of secondary prevention therapy for AMI during the index hospitalization. For this purpose, we have analyzed 1083 consecutive patients with AMI to a tertiary referral hospital in Hong Kong and assessed discharge prescription rates of secondary prevention therapies (aspirin, beta-blockers, statins, and ACEI/ARBs). Multivariate analysis was used to identify independent predictors of discharge medication, and Kaplan-Meier survival curve was used to evaluate 12-month survival. Overall, prescription rates of aspirin, beta-blocker, statin, and ACEI/ARBs on discharge were 94.8%, 64.5%, 83.5%, and 61.4%, respectively. Multivariate analysis showed that prior use of each therapy was an independent predictor of prescription of the same therapy on discharge: aspirin (odds ratio (OR) = 4.8, 95% CI = 1.9-12.3, < 0.01), beta-blocker (OR = 2.5, 95% CI = 1.8-3.4, < 0.01); statin (OR = 8.3, 95% CI = 0.4-15.7, < 0.01), and ACEI/ARBs (OR = 2.9, 95% CI = 2.0-4.3, < 0.01). Passive continuation of prior medication was associated with higher 1-year mortality rates than active initiation in treatment-naïve patients (aspirin (13.7% vs. 5.7%), beta-blockers (12.9% vs. 5.6%), and statins (11.0% vs. 4.6%); all < 0.01). Overall, the use of secondary prevention medication for AMI was suboptimal. Our findings suggested that the practice of passive continuation of prior medication was prevalent and associated with adverse clinical outcomes compared to active initiation of secondary preventive therapies for acute myocardial infarction during the index hospitalization.
二级预防治疗可降低急性心肌梗死(AMI)后的死亡和再梗死,但在临床实践中未得到充分利用。这种治疗差距的机制尚未得到很好的确定。在这项研究中,我们探讨并评估了在指数住院期间被动延续与主动启动 AMI 二级预防治疗对 AMI 的影响。为此,我们分析了香港一家三级转诊医院的 1083 例连续 AMI 患者,并评估了二级预防治疗(阿司匹林、β受体阻滞剂、他汀类药物和 ACEI/ARB)的出院处方率。采用多变量分析确定出院药物的独立预测因素,并采用 Kaplan-Meier 生存曲线评估 12 个月的生存率。总体而言,阿司匹林、β受体阻滞剂、他汀类药物和 ACEI/ARB 的出院处方率分别为 94.8%、64.5%、83.5%和 61.4%。多变量分析显示,每种治疗方法的既往使用是出院时开具相同治疗方法处方的独立预测因素:阿司匹林(比值比(OR)=4.8,95%CI=1.9-12.3,<0.01)、β受体阻滞剂(OR=2.5,95%CI=1.8-3.4,<0.01);他汀类药物(OR=8.3,95%CI=0.4-15.7,<0.01)和 ACEI/ARB(OR=2.9,95%CI=2.0-4.3,<0.01)。与治疗初治患者的主动启动相比,被动延续既往药物与更高的 1 年死亡率相关(阿司匹林(13.7%比 5.7%)、β受体阻滞剂(12.9%比 5.6%)和他汀类药物(11.0%比 4.6%);均<0.01)。总体而言,AMI 二级预防药物的使用并不理想。我们的研究结果表明,与指数住院期间主动启动急性心肌梗死二级预防性治疗相比,被动延续既往药物的做法更为普遍,并与不良临床结局相关。